Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic CRPC

[Seasid]

Patients with mCRPC who received first-line ARATs had better survival if they had a PSA nadir≦2 ng/mL or a TTN≧7 months. Further study is needed to determine if an early switch in therapy for those in whom neither is achieved may impact OS.

bmccancer.biomedcentral.com...

[dhccpa]

I'm 4.5+ years on just Lupron. I assume no point in switching at this point, but I'm trying to follow developments on AA.

[Seasid in reply to dhccpa]

Asians respond better to ADT treatment according to the authors of the study. I am also sticking to the ADT only until I can.

[MarkBC in reply to dhccpa]

I had docetaxel to start and over 4 years of just ADT. When my PSA started rising, my oncologist added abiraterone. She believed in holding back the abiraterone until needed. Since I started it in September, my PSA has dropped to the lowest point ever ... undetectable. My bone mets are no longer visible on scans. I'm 5 years into this journey and looking forward to more years to come.

[dhccpa in reply to MarkBC]

I never had chemo. Maybe I'll do that before AA.

[PSAed in reply to MarkBC]

Fantastic news, congratulations ! I sincerely hope your expectations are met or exceeded. I have to say I just love good news stories, they're such a boost. Best Wishes